Live feed07:00:00·54dSave storyPRReleasevia QuantisnowInsmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026ByQuantisnow·Wall Street's wire, on your screen.INSMInsmed IncorporatedHealth Care